Gene · 4100
Papers1,534
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,534
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| mRNA Multipeptide-HLA Class II Immunotherapy for Melanoma. | Cells | 2025 | 41002395 | PubTator, text mining | PubMed |
| DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets. | Mol Ther Oncol | 2025 | 40791813 | PubTator, text mining | PubMed |
| Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor. | Front Immunol | 2025 | 40746549 | PubTator, text mining | PubMed |
| Immunotherapy in Glioblastoma: An Overview of Current Status. | Clin Pharmacol | 2025 | 40735070 | PubTator, text mining | PubMed |
| Multiple Tumor-related autoantibodies test enhances CT-based deep learning performance in diagnosing lung cancer with diameters < 70 mm: a prospective study in China. | BMC Pulm Med | 2025 | 40731282 | PubTator, text mining | PubMed |
| Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation. | Mol Ther Nucleic Acids | 2025 | 40673161 | PubTator, text mining | PubMed |
| Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges. | World J Transplant | 2025 | 40535484 | PubTator, text mining | PubMed |
| Correction to "Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China". | Cancer Med | 2025 | 40395161 | PubTator, text mining | PubMed |
| Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China. | Cancer Med | 2025 | 40152485 | PubTator, text mining | PubMed |
| A panel of cancer testis antigens in squamous cell carcinoma of the lung, head and neck, and esophagus: implication for biomarkers and therapeutic targets. | Discov Oncol | 2025 | 39864021 | PubTator, text mining | PubMed |
| MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 M5C Modification. | Adv Sci (Weinh) | 2025 | 39716999 | PubTator, text mining | PubMed |
| Construction and characterization of a novel secreted MsC-CAR-T cell in solid tumors. | Cancer Lett | 2025 | 39642980 | PubTator, text mining | PubMed |
| A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myeloma. | Haematologica | 2025 | 39279443 | PubTator, text mining | PubMed |
| Diagnostic value of multi-tumor-associated autoantibody expression in esophageal squamous cell carcinoma and correlation of clinical features. | Front Immunol | 2024 | 39744640 | PubTator, text mining | PubMed |
| The diagnostic efficacy of seven autoantibodies in early detection of ground-glass nodular lung adenocarcinoma. | Front Oncol | 2024 | 39659784 | PubTator, text mining | PubMed |
| The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer. | Biomark Med | 2024 | 39360656 | PubTator, text mining | PubMed |
| AI-enhanced diagnostic model for pulmonary nodule classification. | Front Oncol | 2024 | 39281372 | PubTator, text mining | PubMed |
| Nomogram for Predicting Efficacy and Prognosis After Chemotherapy for Advanced NSCLC. | Clin Respir J | 2024 | 39118382 | PubTator, text mining | PubMed |
| Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples. | Clin Chem | 2024 | 39039866 | PubTator, text mining | PubMed |
| First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. | J Immunother Cancer | 2024 | 39038917 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4100/papers?page=2